NEWSROOM | Galderma

Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)

Cetaphil Taps Rachel Brosnahan as Creative Consultant for New “Up Close and Sensitive” Digital Campaign

Galderma To Present Five Abstracts in Support of Novel Aesthetics Solutions and Pipeline at ASDS 2020 Annual Meeting

Cetaphil® Unveils Premium Product Line with New HydroSensitiv™ Complex That Delivers 48-Hour Hydration

On International Kissing Day, Galderma Shares First-of-its-Kind Phase IV Kissability Study Results Showing Both Subject and Partner Satisfaction with Restylane® Kysse

Galderma global research reveals struggles of people with rosacea and psoriasis of the face experiencing a lack of control and impact on mental wellbeing

Galderma Announces Top-Line Results of Clinical Study Showing Patients Treated with Dysport® (abobotulinumtoxinA) Achieved High Levels of Satisfaction and Natural-Looking Results with Two Treatments Per Year

Galderma Receives FDA Approval For Restylane® Kysse, A New Hyaluronic Acid (HA) Filler Specifically Designed And Indicated To Add Fullness To The Lips And Help Smooth The Wrinkles Above The Mouth

Galderma closes the sale of Bübchen to Dallmann’s Pharma

CETAPHIL by Galderma unites forces to focus on hand health and safety with their "In Good Hands" initiative to fight COVID-19

Galderma receives approval for Restylane® Vital™, Restylane® Lyft™, and Restylane® Lidocaine in China

Galderma demonstrates continued commitment to aesthetic education by offering new series of digital webinars*